Should A1c remain the gold standard for routine monitoring of glucose control in people with diabetes, or is it time to shift ...

DXCM gains from CGM demand, Medicare coverage expansion and its new G7 15-day sensor, but rising competition and manufacturing investments may pressure margins.

Senseonics (Nasdaq:SENS) announced new data from a real-world study demonstrating the sustained performance of its Eversense 365 CGM.

New data shows positive real-world impact of the world’s first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes Eversense 365 delivered ...

The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult without diabetes, are these extra data points worth $99 per month?

DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...

The Greater Chennai Corporation (GCC) Council on Friday passed a resolution to install environmental sensors at 75 locations to provide real-time data of 18 different parameters of pollution to the ...

Worldwide Revenue: $1.26 billion for Q4 2025, up 13% from Q4 2024. US Revenue: $892 million for Q4 2025, an increase of 11% from Q4 2024. International Revenue: $368 million for Q4 2025, up 18% from ...

Feb 12 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...

Revenue grew 13% year-over-year to $1.260 billion on a reported basis and 12% year-over-year on an organic 1 basis. U.S. revenue grew 11% and international revenue grew 18% on a reported basis and 15% ...

Dexcom is already working on its G8 sensor for continuous glucose monitoring (CGM). But before you get too excited, the product is still a couple of years out, CEO Jake Leach told MD+DI during the J.P ...

When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...